 LEIDEN, Netherlands CAMBRIDGE, Mass., Feb. 16, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR the Company, a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases IRDs, today announced that the Company will host an Expert Perspectives call on February 22, 2021 at 12:00pm EST. The call will feature a discussion between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics and Paul Yang, MD, PhD about disease education and endpoints in Usher syndrome and non-syndromic Retinitis Pigmentosa nsRP. Areas of focus for the session will include which vision measures are most informative in the context of this disease setting, the role of patient baseline and disease progression, and an overview of the objectives of the Phase 12 Stellar trial of QR-421a. 